Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy. Randomized phase 2 trial of plinabulin (NPI-2358) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback